1. Home
  2. SLRC vs PHAR Comparison

SLRC vs PHAR Comparison

Compare SLRC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLR Investment Corp.

SLRC

SLR Investment Corp.

HOLD

Current Price

$13.34

Market Cap

803.0M

Sector

Finance

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$13.10

Market Cap

917.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRC
PHAR
Founded
2007
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
803.0M
917.4M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
SLRC
PHAR
Price
$13.34
$13.10
Analyst Decision
Hold
Strong Buy
Analyst Count
7
3
Target Price
$15.14
$38.33
AVG Volume (30 Days)
558.8K
14.0K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
10.49%
N/A
EPS Growth
N/A
N/A
EPS
0.31
N/A
Revenue
N/A
N/A
Revenue This Year
$1.09
$10.04
Revenue Next Year
N/A
$2.51
P/E Ratio
$42.05
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$12.83
$9.54
52 Week High
$17.20
$21.34

Technical Indicators

Market Signals
Indicator
SLRC
PHAR
Relative Strength Index (RSI) 41.25 38.40
Support Level $12.83 $11.84
Resistance Level $15.65 $13.44
Average True Range (ATR) 0.24 0.42
MACD 0.04 0.12
Stochastic Oscillator 88.03 52.85

Price Performance

Historical Comparison
SLRC
PHAR

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: